(Reuters) -Anglo-Swedish drugmaker AstraZeneca (NASDAQ:) on Thursday raised its gross sales and revenue forecast for 2024 and topped analyst expectations for second-quarter income, buoyed by demand for its therapies for most cancers and uncommon ailments.
Gross sales within the firm’s prime enterprise, oncology, grew 19% at fixed forex charges to $5.33 billion and accounted for 41% of the full, whereas different divisions, resembling uncommon ailments and respiratory and immunology, additionally raked in double-digit development.
AstraZeneca’s drug pipeline has developed considerably beneath CEO Pascal Soriot since he took over greater than a decade in the past, and new applied sciences resembling antibody-drug conjugates are making up a rising proportion of its portfolio of future most cancers therapies.
“In the year to date we have continued to make encouraging progress with several disruptive technologies … all of which have the potential to drive our growth beyond 2030,” CEO Soriot mentioned.
AstraZeneca now expects each 2024 income and core earnings per share to extend by a mid-teens share at fixed forex charges.
The corporate beforehand anticipated income and revenue to extend by a low double-digit to low-teens share.
Analysts, on common, at present count on 2024 EPS of $8.11 and income of $51.62 billion – translating to development of about 11.7% and 12.7%, respectively, in line with LSEG IBES information.
Complete income rose 17% on a constant-currency foundation to $12.94 billion for the three months ended June, whereas core earnings got here in at $1.98 per share for the biggest London-listed firm by market worth.
Analysts, on common, had been anticipating revenue of $1.98 per share on income of $12.6 billion for the quarter, in line with a company-compiled consensus.
